Javelin Oncology, Inc.
NH · Founded 2017 · CIK 0001796219 · Biotech · Private
Personalized cancer therapeutics matched to patient tumor genomic profiles using precision oncology sequencing and targeting
aclys.bio →- Grants
- $1.2M
- 4 awards
- Sector median: 1
- Raised
- $1.5M
- 1 Form D · Dec 2019
- 82 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 6
- 0 granted · 6 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20182019202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · A Novel Target for CAR T Cell Therapy Using Precision Oncology Approaches | $293,897 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · A Novel Target for CAR T Cell Therapy Using Precision Oncology Approaches | $293,897 | |
| Private capital raised | Form D · SEC | $1,500,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Chimeric Switch Receptors to Potentiate CAR T Cell Therapy for Solid Tumor Cancers | $328,946 | |
| Federal grant | Department of Health and Human Services · Phase I · Chimeric Switch Receptors to Potentiate CAR T Cell Therapy for Solid Tumor Cancers | $328,946 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1842 | SCRIPT BIOSCIENCES INC | — | — |
| 1843 | HCO ANTIBODY, INC. | — | — |
| 1844 | MARIPOSA HOLDINGS GROUP, INC. | — | $280K |
| 1845 | Javelin Oncology, Inc. | — | $1.5M |
| 1846 | ABILITY Network Inc. | — | $20M |
| 1847 | Biena, LLC | — | $11M |
| 1848 | EMMYON, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Eric AchtmanDirector
- Anthony CooperExecutive Officer
- Matthew MartinExecutive Officer
- Jake RederDirector
- Daniel RhodesDirector · Executive Officer
Patents
- ANTI-ADAM12 Antibodies And Chimeric Antigen Receptors, And Compositions And Methods Comprisingapplication
- ANTI-ALPPL2 Antibodies And Chimeric Antigen Receptors, And Compositions And Methods Of Useapplication
- ANTI-ALPPL2 Antibodies And Chimeric Antigen Receptors, And Compositions And Methods Of Useapplication
- ANTI-ADAM12 Antibodies And Chimeric Antigen Receptors, And Compositions And Methods Comprisingapplication
- ANTI-ADAM12 Antibodies And Chimeric Antigen Receptors, And Compositions And Methods Comprisingapplication
- ANTI-ALPPL2 Antibodies And Chimeric Antigen Receptors, And Compositions And Methods Of Useapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.